Description: Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It provides various medicines for allergy, blood circulation and memory, bone and joint, kids, liver and digestive, eye, heart, pain, skin, sleeping, well-being, herbal, and cough and cold care, as well as vitamins, probiotics, medical and sports nutrition, and men's and women's care products; and prescription medicines in the areas of anti-allergic, anti-infective, central nervous system, cardio vascular system, dermatology, diabetes, gastroenterology, gynaecology, nephrology, oncology, ophthalmology, orthopaedic, pain, respiratory, rheumatology, and urology. The company also offers logistical and marketing services for the sale of goods manufactured by third parties, as well as involved in the software design, development, and other services business. It operates in the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States. The company was incorporated in 1982 and is headquartered in Bangkok, Thailand. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited.
Home Page: www.megawecare.com
909, Ample Tower
Bangkok,
10260
Thailand
Phone:
66 2 769 4222
Officers
Name | Title |
---|---|
Mr. Vivek Dhawan | CEO, Chief Coach & Exec. Director |
Mr. Thomas Abraham | CFO & Exec. Director |
Mr. Deepak Panjwani | Chief Risk & Compliance Officer |
Mr. Paramjit Singh Sawhney | Pres of International |
Mr. Girish Wadhwa | Pres of Myanmar |
Mr. Manoj Gurbuxani | Deputy Chief Financial Officer |
Ms. Duangnapa Tongsiri | Pres of Mega We Care Thailand |
Ms. Sujintana Boonworapat | Corp. Sec. |
Mr. Apichai Chanjarusiri | Manufacturing Director of Thailand |
Exchange: BK
Country: TH : Thailand
Currency: Thai baht (฿)
Forward PE: | 16.7785 |
---|---|
Trailing PE: | 18.5634 |
Price-to-Book MRQ: | 4.7826 |
Price-to-Sales TTM: | 2.7024 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 0 |